Karen Klahn, MBA, is affiliated with Takeda Pharmaceuticals USA, Inc. in Lexington, Massachusetts. Her publications focus on Attention-Deficit/Hyperactivity Disorder (ADHD) in both children, adolescents, and adults, with particular attention to experiences during the COVID-19 pandemic. Klahn has contributed to studies examining caregiver and patient perspectives on managing ADHD amid pandemic-related challenges. Her work appears in Psychiatrist.com, including The Journal of Clinical Psychiatry and The Primary Care Companion for CNS Disorders.
1 Read counts for articles published before 2020 may include some non-human traffic.
2 Citation counts provided by Crossref.
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.
